COMP <GO>
NSRX vs NNVC // REVENUE GROWTH (YOY)
Nasus Pharma Ltd. (NYSE) VS. NanoViricides Inc. (NYSE) • 15-METRIC TALLY: NSRX 2
— NNVC 1
■ METRIC PARITY
LAST: $3.19 (-4.49%) • MKT CAP: $37.4M
revenue-growth
—
LAST: $1.43 (-1.38%) • MKT CAP: $36.5M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NSRX VS. NNVC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NSRX | NNVC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.20% | -23.37% | +10.17 | NSRX | /fcf-yield <GO> |
| Operating Margin | -0.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -0.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.3 | 47.0 | -8.77 | NNVC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.4M | $36.5M | $836.1K | NSRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NSRX REV | NNVC REV | NSRX GROSS % | NNVC GROSS % | NSRX FCF | NNVC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $0 | — | — | -$4.9M | -$8.5M |
| FY 2024 | $0 | $0 | — | — | -$665.0K | -$6.5M |
| FY 2023 | $0 | $0 | — | — | -$1.0M | -$5.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NSRX // BETA —
NNVC // BETA —